Patents by Inventor Hans Hofstetter
Hans Hofstetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235038Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: July 7, 2022Publication date: July 27, 2023Inventors: Franco E. Di Padova, Hermann GRAM, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20190270804Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: May 15, 2019Publication date: September 5, 2019Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 10344084Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 11, 2017Date of Patent: July 9, 2019Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20170355762Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 11, 2017Publication date: December 14, 2017Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 9765140Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2015Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20150152178Abstract: An IL-17 binding molecule, in particular .an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2015Publication date: June 4, 2015Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Publication number: 20140079719Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8617552Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: January 13, 2012Date of Patent: December 31, 2013Assignee: Novarts AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20120107325Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: January 13, 2012Publication date: May 3, 2012Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8119131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2010Date of Patent: February 21, 2012Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 7807155Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 4, 2005Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20100215666Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2010Publication date: August 26, 2010Inventors: FRANCO E. DI PADOVA, HERMANN GRAM, HANS HOFSTETTER, MARGIT JESCHKE, JEAN-MICHEL RONDEAU, WIM VAN DEN BERG
-
Publication number: 20090280131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 4, 2005Publication date: November 12, 2009Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20040047860Abstract: MCP-1 binding molecules are provided comprising at least one immunoglobulin heavy chain variable domain (VH) comprising hypervariable regions CDR1, CDR2 and CDR3 of sequence as defined, for use in the treatment of MCP-1 or eotaxin-mediated diseases or disorders.Type: ApplicationFiled: July 18, 2003Publication date: March 11, 2004Inventors: Peter Hiestand, Hans Hofstetter, Trevor Glyn Payne, Roman Urfer, Franco E Di Padova
-
Patent number: 5081028Abstract: The invention concerns polypeptides related to human immunoglobulin E binding factors (IgE-Bfs), mRNa, DNAs and hybrid vectors coding for said polypeptides, hosts containing said hydrid vectors, processes for the preparation of said polypepties, mRNAs, DNAs, hybrid vectors, and hosts. The polypeptides can be used for the prevention and/or the treatment of allergic diseases, and accordingly the invention concerns also pharmaceutical preparations containing them.Type: GrantFiled: November 21, 1990Date of Patent: January 14, 1992Assignee: Ciba-Geigy CorporationInventors: Hans Hofstetter, Erich Kilchherr, Albert Schmitz
-
Patent number: 4993886Abstract: The new invention concerns the regulation of air volume in a conveying system comprising an air collecting line (37) in which the air volume and the corresponding air velocity, respectively, is regulated in the individual conveying pipelines (30-36) by a lifting body (4) resembling an airfoil. The latter works like a throttle flap and moves from an incidence angle (.alpha., .beta.) of at least 10 degrees in the completely open position to 90 degrees in the closed position as a result of the lifting moments acting on it. The lifting body (4) itself regulates the air volume by means of blocking the air line cross section to a greater or lesser extent, wherein a balance is adjusted in every case between the air forces and lifting moments, respectively, which act at the lifting body (4) so as to be directed in a closing position and a counterweight (5) or countertorque, respectively, acting at the lifting body (4) in the opening direction.Type: GrantFiled: April 21, 1989Date of Patent: February 19, 1991Assignee: Buehler AGInventor: Hans Hofstetter